Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-chloro-6-(4-hydroxyphenyl)-2-naphthol is a synthetic small molecule with the molecular formula C16H11ClO2 and a molecular weight of approximately 270.71 g/mol. It features a phenylnaphthalene skeleton, consisting of a naphthalene core bound to a phenyl group substituted with hydroxy and chloro groups. This compound has been studied as an experimental ligand for estrogen receptor beta (ERβ), where it acts as an inhibitor. Structural studies have shown that it can bind selectively to ERβ, mimicking the binding orientation of genistein but with potentially higher affinity and selectivity due to its unique scaffold modifications[2][9]. There are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-chloro-6-(4-hydroxyphenyl)-2-naphthol.